Nektar Therapeutics Stock News

Clinical-stage biotech Nektar Therapeutics (NKTR 15.06%) had some encouraging news to report from the lab about one of its investigational medicines on Thursday. As often happens in such circumstances, investors flocked to the stock, and it closed the trading session a bit more than 15% higher.

Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitis High dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments at completion of 16-week induction period Interim data presented for patients who received placebo during induction period and crossed over to receive 24 weeks of treatment wi...

SAN FRANCISCO , Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy of Dermatology and Venereology (EADV) Congress being held in Paris, France from September 17-20, 2025.

Nektar Therapeutics (NKTR 7.73%) stock surged by more than 20% in the week to Friday morning. The move wasn't so much caused by anything specific to Nektar's drug development program.

SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C.

Nektar Therapeutics (NASDAQ:NKTR ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief Research & Development Officer Korin Franklin - Corporate Participant Sandra A.

Biotech Nektar Therapeutics (NKTR 6.02%) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today.

Nektar (NKTR) Q2 Revenue Falls 52%